Royalty Pharma plc Gain (Loss) on Extinguishment of Debt
Royalty Pharma plc (RPRX) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2025-02-12
- Royalty Pharma plc gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was -$419.00K.
- Royalty Pharma plc gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- Royalty Pharma plc gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was -$358.00K.
- Royalty Pharma plc gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Royalty Pharma plc gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- Royalty Pharma plc gain (loss) on extinguishment of debt for fiscal 2022 was -$419.00K.
- Royalty Pharma plc gain (loss) on extinguishment of debt for fiscal 2021 was -$358.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2022-12-31 | -$419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$419.00K 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$358.00K derived: sum of 2 quarters · filed 2024-02-15 | -$358.00K derived: sum of 3 quarters · filed 2024-02-15 | -$358.00K 10-K · filed 2024-02-15 |
| 2021-09-30 | -$358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$358.00K derived: sum of 2 quarters · filed 2022-11-08 | -$358.00K 10-Q · filed 2022-11-08 | -$358.00K derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-02-15 | -$24.87M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-02-15 | -$24.87M derived: sum of 3 quarters · filed 2023-02-15 | -$24.87M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$24.87M derived: sum of 2 quarters · filed 2023-02-15 | -$24.87M derived: sum of 3 quarters · filed 2023-02-15 | -$30.27M 10-K · filed 2023-02-15 |
| 2020-09-30 | -$24.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$24.87M derived: sum of 2 quarters · filed 2021-11-10 | -$30.27M 10-Q · filed 2021-11-10 | -$30.27M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$5.41M 10-Q · filed 2021-08-11 | -$5.41M derived: sum of 3 quarters · filed 2022-02-15 | -$5.41M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$5.41M 10-Q · filed 2021-05-11 | -$5.41M derived: sum of 2 quarters · filed 2022-02-15 | -$5.41M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |